Average proportion of days covered (PDC) for individuals with antiplatelet therapy during the 12 months following implantation of a coronary artery drug-eluting stent (DES) or a bare-metal stent (BMS).
The sum of the days covered by the days’ supply of all antiplatelet prescriptions during the days measured in the denominator
Denominator
1.15 Denominator
The sum of the days measured for all individuals who undergo a coronary artery drug-eluting stent (DES) or bare-metal stent (BMS) placement at any time during the first 12 months of the 24-month measurement period and have at least two prescriptions for antiplatelet therapy during the 12 months following stent placement
Exclusions
Exclusions
Individuals with a history of contraindication(s) to antiplatelet therapy are excluded. Contraindications include peptic ulcer disease, intracranial hemorrhage, and gastrointestinal (GI) bleed.
Measure Record
Most Recent Endorsement Activity
Measure Retired and Endorsement Removed Cardiovascular Spring Cycle 2018
Initial Endorsement
Last Updated
Removal Date
Point of Contact
Steward Organization
Centers for Medicare & Medicaid Services
Steward POC email
Helen.Dollar-Maples@cms.hhs.gov
Steward Organization Copyright
Limited proprietary coding is contained in the measure specifications for user convenience. Use of these codes may require permission from the code owner or agreement to a license.
Public Comments